IOL Chemicals and Pharmaceuticals Limited will host a virtual group meeting with investors and analysts on September 28, 2026. The event is organized by Nuvama Private Client Group (PCG). This interaction provides a platform for stakeholders to engage with the company's management regarding its recent performance.

The meeting is scheduled as a group meeting in virtual mode. It is conducted pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The primary objective is to facilitate communication between the company and the investment community.

Meeting details and scope

The discussion during the conference will be strictly limited to past financial results and information already available in the public domain. The company has explicitly stated that no unpublished price-sensitive information (UPSI) will be disclosed during this session. This ensures compliance with regulatory standards regarding fair disclosure.

Regulatory compliance and notes

The schedule for the analyst and institutional investor meeting is subject to change due to unforeseen circumstances. Such changes may arise from last-minute adjustments in investor or broker participation, or cancellations. The company filed this notice with both the National Stock Exchange of India Ltd and BSE Limited on September 23, 2026.

Abhay Raj Singh, Senior Vice President and Company Secretary, signed the digital notice confirming the schedule. Stakeholders are advised to refer to official company communications for any updates regarding the event logistics.

IOL Chemicals and Pharmaceuticals Limited has released the full transcript of its business update conference call held on Friday, September 11, 2026. The company previously disclosed the availability of the audio recording on September 17, 2026, pursuant to SEBI regulations.

The disclosure was made under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Abhay Raj Singh, Senior Vice President and Company Secretary, signed the communication on behalf of the board.

Call Details

The transcript provides detailed insights into three strategic growth initiatives involving a proposed investment of approximately ₹500 crore. Management outlined plans to expand Ibuprofen capacity by 6,000 MTPA, establish a new CDMO facility with a capacity of 1,500 million tablets per annum, and set up a dedicated specialty chemical facility under a tolling arrangement.

These initiatives are expected to contribute an incremental 25% to 30% to the top line over the coming years once fully operationalized, likely by FY29. The investments are planned to be funded through internal accruals, with around 30% of the overall funding requirements already incurred.

Key Initiatives

Management noted that the Ibuprofen expansion leverages backward integration and is expected to reach optimal utilization in FY28-FY29. The CDMO facility, which has received EU GMP certification, targets the European region and is expected to be fully operationalized in the next financial year.

Regulatory Compliance

The filing serves as a mandatory regulatory update under SEBI norms. It ensures transparency by providing market participants with direct access to management commentary from the recent investor interaction. The transcript is available on the company’s official website.